Taligen Therapeutics announced the close of a $65M Series B financing led by Alta Partners and Clarus Ventures and with ongoing participation from existing partners Sanderling Ventures, Tango and High Country Venture.
All I can say is ‘WOW’! I would be willing to bet a dollar that there is not a larger Series B financing anywhere last year or this year. Talk about a powerful syndicate of investors, this deal has attracted institutional dollars from Sand Hill Rd, San Fran, Boston and Boulder. Well done Dr. Emlen!
Taligen Therapeutics, Inc. is a development-stage biotechnology company with novel technology and expertise focused on modulation and control of the complement system. The complement system is believed to be a critical component in the initiation of inflammation. Complement system activation is characteristic of many human diseases, including asthma, macular degeneration, rheumatoid arthritis and immune renal disease.
Taligen’s lead products are monoclonal antibodies and recombinant fusion proteins which target key factors in the alternative complement pathway. These products are in preclinical stages of development to treat systemic as well as local inflammatory conditions.
***NOTE*** Read the new eBook CLSDF 2007 - What's In A Year? (HERE)!
If you enjoyed this post get free email or RSS updates (here).
Friday, February 01, 2008
Taligen Therapeutics: $65M Series B
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment